NATTO: Received EU grant together with CARIM

Vitamin K2 Research Commitment - NattoPharma and the Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht have entered into an Agreement to Develop New Vitamin K2 technologies

2013-11-05 NattoPharma and Cardiovascular Institute Maastricht Enter into research AgreementOSLO, NORWAY – NattoPharma, producers of MenaQ7® Vitamin K2 ingredients, today announces that the company has signed a new and long term research agreement with the Cardiovascular Research Institute Maastricht, (CARIM), and University of Maastricht. This agreement provides NattoPharma a possibility to evaluate new Vitamin K2 technologies, create proof of concept studies for novel delivery systems and evaluate the impact of Vitamin K2 on human health.

NattoPharma and CARIM recently successfully applied and received a grant from the Dutch government to investigate effects of vitamin K supplementation on cardiovascular disease in patient and volunteer serum / plasma reflected by a biohybrid platform based on human vascular smooth muscle cells.

“This achievement confirms the success of NattoPharma strategy to secure a substantial part of our product development and innovation project costs through public funding, grants and in collaboration with high-level scientific institutions”, says Frode M. Bohan, Chairman of the Board in NattoPharma.

Dr. Leon Schurgers of CARIM states: “The agreement with NattoPharma will strengthen our seminal research to understand the essential Vitamin K2 and its pivotal contribution to healthy aging”.

NattoPharma already collaborates with VitaK at the University of Maastricht. In this collaboration the recently published three-year study demonstrated bone health and bone strength benefits of MenaQ7 Vitamin K2 in healthy post-menopausal women, published in the journal “Osteoporosis International.” The new agreement with CARIM complements and expands NattoPharma’s R&D efforts.

“Through the agreement with CARIM NattoPharma continues the efforts to explore biological vitamin K2 effects”, said Hogne Vik, CEO. “With this agreement NattoPharma will consolidate our position as the dominating vitamin K2 company conducting therapeutic human clinical research to validate Vitamin K2’s benefits”.

About NattoPharma and MenaQ7®

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in an exclusive research and development collaboration with VitaK, University in Maastricht, The Netherlands, working to substantiate the health benefits of natural vitamin K2.

For more information, please contact: 
 
Hogne Vik, MD, PhD,
CEO
+47 975 35 326 / hogne.vik@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.